FY2025 · ended Dec 31, 2025 · Revenue $54.03M, +48.0% YoY · Filed Feb 12, 2026
Agios Pharmaceuticals, Inc. (AGIO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $54.0 million and a net loss of $412.8 million. Free cash flow was -$377.3 million. As of Jun 30, 2026 it held $964.8 million in cash and investments and $31.2 million in total debt.
Revenue (TTM)
$98.34M
+140.6% vs year-ago TTM
Net income (TTM)
$-411.29M
-163.3% vs year-ago TTM
Operating cash flow (TTM)
$-360.60M
+11.2% vs year-ago TTM
Free cash flow (TTM)
$-365.25M
+10.7% vs year-ago TTM
EPS (TTM)
$-7.01
-163.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
58.59M
+2.3% vs prior year
Net cash
$933.66M
as of Jun 30, 2026
Operating margin
-466.8%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AGIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1439222
- Former names
- AGIOS PHARMACEUTICALS INC (until Jul 16, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $54.0M | $36.5M | $26.8M | $14.2M | — |
| Operating income | -$472.1M | -$425.7M | -$391.5M | -$389.0M | -$378.4M |
| Net income | -$412.8M | $673.7M | -$352.1M | -$231.8M | $1.6B |
| Diluted EPS | -$7.12 | $11.64 | -$6.33 | -$4.23 | $26.55 |
| Operating cash flow | -$373.0M | -$389.8M | -$296.1M | -$309.5M | -$407.3M |
| Free cash flow | -$377.3M | -$391.5M | -$297.1M | -$314.4M | -$413.1M |
| Total assets | $1.3B | $1.7B | $937.1M | $1.2B | $1.4B |
| Total liabilities | $104.1M | $122.2M | $126.1M | $137.9M | $145.8M |
| Stockholders' equity | $1.2B | $1.5B | $811.0M | $1.1B | $1.3B |
| Cash and investments | $1.2B | $1.5B | $806.4M | $1.1B | $1.3B |
| Total debt | $40.2M | $57.0M | $72.0M | $85.7M | $97.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 18, 2026 | Jun 18, 2026 |
| 10-Q | Quarterly report | Apr 29, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
Apr 29, 2026 | Apr 29, 2026 |
| ARS | Annual report to shareholders | Apr 24, 2026 | Dec 31, 2025 |
All 1002 Agios Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.